Comparison of Tenecteplase and Alteplase in Relation to Treatment Timing for Acute Ischemic Stroke
Overview
This study compares treatment workflow times between tenecteplase and alteplase in patients with acute ischemic stroke.
Background
Timely initiation of reperfusion therapy is crucial for improving outcomes in acute ischemic stroke. Tenecteplase offers a streamlined administration process compared to alteplase. Understanding the differences in treatment timing between these two agents is essential for stroke care.
Data Highlights
No numerical data provided in the source material.
Key Findings
Tenecteplase allows for a single 5- to 10-second bolus, compared to alteplase's bolus plus 60-minute infusion.
Tenecteplase has a longer free plasma half-life.
Hospitals categorized as high utilizers of tenecteplase treated 75% or more of thrombolytic cases with this agent.
The study utilized data from the Get With The Guidelines–Stroke database, capturing over 75% of stroke admissions in the US.
Patients treated with tenecteplase may experience shorter door-to-needle and door-in-door-out times.
Clinical Implications
The findings suggest that tenecteplase may enhance the efficiency of thrombolytic therapy in acute ischemic stroke. Clinicians should consider the implications of treatment timing on patient outcomes when selecting thrombolytic agents.
Conclusion
The study indicates differences in treatment workflow times between tenecteplase and alteplase.
by Steven J. Warach, Jeremy M. Weber, Brooke Alhanti, Steven R. Messé, Lee H. Schwamm, Gregg C. Fonarow, Kevin N. Sheth, Eric E. Smith, Michael T. Mullen, Gisele Sampaio Silva, Brian Mac Grory, Ying Xian, Jeffrey L. Saver
